Association of p21, p21 p27 and p21 p53 Status to Histological Subtypes and Prognosis in Low-stage Epithelial Ovarian Cancer

被引:2
|
作者
Skirnisdottir, Ingiridur [1 ]
Seidal, Tomas [2 ]
机构
[1] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[2] Halmstad Med Cent Hosp, Dept Pathol, Halmstad, Sweden
关键词
Ovarian cancer; histological subtypes; prognosis; cyclin kinase inhibitors; p21; p53; p21p27; CYCLE REGULATORY PROTEINS; CELL-PROLIFERATION; C-MYC; EXPRESSION; P21(WAF1/CIP1); CARCINOMA; P27(KIP1); P16(INK4A); IMPACT; TP53;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The objective of this study was to evaluate the prognostic value of p21 alone and in combination with p53 or p27 for different histological subtypes of epithelial ovarian cancer and disease-free survival. Patients and Methods: The specimens were obtained at primary surgery from a series of 129 ovarian carcinomas in FIGO stages I-II. The technique of tissue microarray and immunohistochemistry was used for detection of positivity of the markers. Results: Positive staining for p21, p27 and p53 was detected in 36%, 58% and 25% of cases, respectively. The p21 status, p27 status and concomitant p21 p27 and p21 p53 status in four subgroups were related to histological subtypes (p=0.016, p=0.036, p=0.004 and p=0.001). Mucinous tumors mostly stained negatively for p27 and concomitantly negatively for p21 and p53. Clear cell tumors generally stained positively for p21 and p27 but negatively for p53. Serous tumors usually stained concomitantly negatively for p21 and positively for p53. In a multivariate Cox regression analysis, FIGO stage, p21 p53 and p53 status were independent prognostic factors for disease-free survival. Conclusion: A subgroup, constituting 25/129 (19%) of the patients with predominantly serous tumors with concomitant p21 negativity and p53 positivity had a poor survival. Another subgroup of 11/129 (9%) patients with non-serous tumors with concomitant p21 and p27 positivity had excellent survival.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [1] Expression of p21 and p27 in gallbladder cancer
    Alsheyab, Fawzi M.
    Ziadeh, Moroug T.
    Bani-Hani, Kamal E.
    SAUDI MEDICAL JOURNAL, 2007, 28 (05) : 683 - 687
  • [2] Are p27 and p21 Cytoplasmic Oncoproteins?
    Blagosklonny, Mikhail V.
    CELL CYCLE, 2002, 1 (06) : 391 - 393
  • [3] Association of p53 and p21 polymorphisms with prostate cancer
    Sivonova, Monika Kmetova
    Vilckova, Marta
    Kliment, Jan
    Mahmood, Silvia
    Jurecekova, Jana
    Dusenkova, Svetlana
    Waczulikova, Iveta
    Slezak, Peter
    Dobrota, Dusan
    BIOMEDICAL REPORTS, 2015, 3 (05) : 707 - 714
  • [4] The clinical significance of p53, p21, and p27 expressions in rectal carcinoma
    Lebe, B
    Sarioglu, S
    Sökmen, S
    Ellidokuz, H
    Füzün, M
    Küpelioglu, A
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2005, 13 (01): : 38 - 44
  • [5] Immunohistchemistry of p53, p21 and p27 proteins in oral SCC.
    Fang, YR
    Wato, M
    Masuno, K
    Li, J
    Jin, Y
    Ueda, Y
    Tanaka, A
    JOURNAL OF DENTAL RESEARCH, 2002, 81 : A298 - A298
  • [6] p21: a monitor of p53 dysfunction in ovarian neoplasia
    Shigemasa, K
    Hu, C
    West, CM
    Moon, SH
    Parham, GP
    Parmley, TH
    Korourian, S
    Baker, VV
    OBrien, TJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997, 7 (04) : 296 - 303
  • [7] p21 and p27 a shared senescence history
    Maria Flores, Juana
    Martin-Caballero, Juan
    Ana Garcia-Fernandez, Rosa
    CELL CYCLE, 2014, 13 (11)
  • [8] p53, p21 and p27 protein expression in head and neck cancer and their prognostic value
    Kapranos, N
    Stathopoulos, GP
    Manolopoulos, L
    Kokka, E
    Papadimitriou, C
    Bibas, A
    Yiotakis, J
    Adamopoulos, G
    ANTICANCER RESEARCH, 2001, 21 (1B) : 521 - 528
  • [9] Incidence of proapoptotic proteins p53 and p21 in epithelial ovarian tumors
    Gajewska, Malgorzata
    Wielgos, Miroslaw
    Panek, Grzegorz
    Marczewska, Janina
    GINEKOLOGIA POLSKA, 2014, 85 (02) : 111 - 116
  • [10] Cell cycle control by p21, p27 and p53 in Merkel cell carcinoma
    Koljonen, V
    Tukiainen, E
    Haglund, C
    Böhling, T
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2209 - 2212